University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
John W. Park, MD

John W. Park, MD

Professor of Clinical Medicine; Director of Novel Therapeutics, Breast Oncology, UCSF

Cancer Center Program Memberships

Breast Oncology

Research Summary

John W. Park, MD, is Professor of Medicine in the Division of Hematology/Oncology at University of California, San Francisco (UCSF) School of Medicine, and Director of Novel Therapeutics in Breast Oncology at the UCSF Comprehensive Cancer Center. Dr. Park received his AB degree at Harvard College, and MD degree at Stanford University School of Medicine. Dr. Park completed his residency training in Internal Medicine at UCLA Medical Center, and fellowship training in Hematology/Oncology at UCSF Medical Center. Dr. Park was also a visiting scientist at Genentech, Inc., where he worked on the development of trastuzumab (HerceptinTM).

Dr. Park has been the recipient of multiple honors and awards, including the ASCO Young Investigator Award, the Career Development Award from the US Department of Defense Breast Cancer Research Program, and Top Doctor from US News & World Report. Dr. Park has authored over 130 published papers and authored or edited 18 books/book chapters on cancer research. Dr. Park is also an inventor with multiple US patents relating to new cancer treatments.

Dr. Park’s major research interests include novel targeted cancer therapeutics and new cancer biomarkers. Dr. Park’s research is well known for its discovery and development of targeted therapeutics using nanoparticle/liposome/immunoliposome technologies. These include nanoliposomal irinotecan (nal-IRI, OnivydeTM), which received US FDA approval in 2015, as well as novel immunoliposome drugs. Dr. Park is also a noted expert in the field of circulating tumor cell and biomarker studies.

Education

Harvard College, A.B., 1982, Biochemical Sciences
Stanford University School of Medicine, M.D., 1986, Medicine
University of California, Los Angeles Medical Center, 1996-1987, Internal Medicine
University of Calilfornia, Los Angeles, Residency, 1989, Internal Medicine
University of California San Francisco, Fellowship, 1992, Medical Oncology & Hematology


Professional Experience

  • 1990-1995
    Visiting Scientist, Dept. of Molecular Biology, Genentech, Inc.
  • 1992-1993
    Instructor in Medicine, Department of Medicine, Division of Hematology/Oncology, UCSF
  • 1993-2003
    Assistant Professor of Medicine, Div. of Hematology/Oncology, UCSF
  • 2003-present
    Director of Novel Therapeutics and Drug Development, Breast Oncology Program, UCSF
  • 2003-2010
    Associate Clinical Professor of Medicine & Neurosurgery, UCSF
  • 2010-present
    Professor of Clinical Medicine; Director of Novel Therapeutics, Breast Oncology

Honors & Awards

  • 1977
    National Merit Scholar
  • 1983
    cum laude in Biochemical Sciences, Harvard College
  • 1984
    Stanford Alumni Medical Student Scholar
  • 1992-1993
    Revlon-UCLA Research Fellowship
  • 1993-1994
    Young Investigator Award, American Society of Clinical Oncology (ASCO)
  • 1994-1998
    Career Development Award, Department of Defense Breast Cancer Research Program

Selected Publications

  1. Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019 Sep; 177(2):401-408.
    View on PubMed
  2. Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clin Cancer Res. 2019 Sep 01; 25(17):5388-5397.
    View on PubMed
  3. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31.
    View on PubMed
  4. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018 06 01; 110(6):560-567.
    View on PubMed
  5. Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499.
    View on PubMed
  6. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 01 01; 31(1):17-28.
    View on PubMed
  7. Peters BA, Park JW, Drmanac R. Pure CTCs, advanced WGS, and precise personalized combination therapies. Oncoscience. 2017 Jul; 4(7-8):75-76.
    View on PubMed
  8. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541.
    View on PubMed
  9. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319.
    View on PubMed
  10. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610.
    View on PubMed
  11. Pugia M, Magbanua MJM, Park JW. Automated Microfluidic Filtration and Immunocytochemistry Detection System for Capture and Enumeration of Circulating Tumor Cells and Other Rare Cell Populations in Blood. Methods Mol Biol. 2017; 1634:119-131.
    View on PubMed
  12. Pugia M, Magbanua MJM, Park JW. Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration. Adv Exp Med Biol. 2017; 994:119-131.
    View on PubMed
  13. Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW. Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC). Methods Mol Biol. 2017; 1634:203-210.
    View on PubMed
  14. Lee JS, Magbanua MJM, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016 12; 160(3):411-424.
    View on PubMed
  15. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22.
    View on PubMed
  16. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49.
    View on PubMed
  17. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166.
    View on PubMed
  18. Magbanua MJ, Das R, Polavarapu P, Park JW. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget. 2015 Oct 13; 6(31):30715-29.
    View on PubMed
  19. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, Esserman L, Park JW, van 't Veer LJ. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73.
    View on PubMed
  20. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206.
    View on PubMed

Go to UCSF Profiles, powered by CTSI